DK3119911T3 - Forbindelser til anvendelse til behandling af alzheimers sygdom hos apoe4+/+ patienter - Google Patents

Forbindelser til anvendelse til behandling af alzheimers sygdom hos apoe4+/+ patienter Download PDF

Info

Publication number
DK3119911T3
DK3119911T3 DK15764560.7T DK15764560T DK3119911T3 DK 3119911 T3 DK3119911 T3 DK 3119911T3 DK 15764560 T DK15764560 T DK 15764560T DK 3119911 T3 DK3119911 T3 DK 3119911T3
Authority
DK
Denmark
Prior art keywords
apoe4
alzheimer
patients
disease
compounds
Prior art date
Application number
DK15764560.7T
Other languages
English (en)
Inventor
Martin Tolar
John Hey
Petr Kocis
Jeremy Yu
Original Assignee
Alzheon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54145492&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3119911(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alzheon Inc filed Critical Alzheon Inc
Application granted granted Critical
Publication of DK3119911T3 publication Critical patent/DK3119911T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/20ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/70ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/20ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
DK15764560.7T 2014-03-21 2015-03-23 Forbindelser til anvendelse til behandling af alzheimers sygdom hos apoe4+/+ patienter DK3119911T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461968595P 2014-03-21 2014-03-21
PCT/US2015/022058 WO2015143447A2 (en) 2014-03-21 2015-03-23 Methods for treating neurological disorders

Publications (1)

Publication Number Publication Date
DK3119911T3 true DK3119911T3 (da) 2023-10-30

Family

ID=54145492

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15764560.7T DK3119911T3 (da) 2014-03-21 2015-03-23 Forbindelser til anvendelse til behandling af alzheimers sygdom hos apoe4+/+ patienter

Country Status (18)

Country Link
US (3) US10471029B2 (da)
EP (2) EP3119911B1 (da)
JP (4) JP6588962B2 (da)
KR (2) KR102448386B1 (da)
CN (1) CN106170563A (da)
AU (1) AU2015230972B2 (da)
CA (1) CA2941415A1 (da)
DK (1) DK3119911T3 (da)
ES (1) ES2960625T3 (da)
FI (1) FI3119911T3 (da)
HR (1) HRP20231172T1 (da)
HU (1) HUE063369T2 (da)
LT (1) LT3119911T (da)
PL (1) PL3119911T3 (da)
PT (1) PT3119911T (da)
RS (1) RS64744B1 (da)
SI (1) SI3119911T1 (da)
WO (1) WO2015143447A2 (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017044840A1 (en) * 2015-09-10 2017-03-16 Alzheon, Inc. Methods of treating neurodegenerative disorders in a particular patient population
CN109475575A (zh) * 2016-07-13 2019-03-15 米托斯株式会社 包含氢作为有效成分的用于预防或治疗轻度认知障碍或认知症的组合物
CN114805211A (zh) 2017-03-21 2022-07-29 润佳(苏州)医药科技有限公司 同位素富集3-氨基-1-丙磺酸衍生物、药物组合物及其用途
CN110003058B (zh) 2018-01-04 2022-01-25 润佳(苏州)医药科技有限公司 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途
CN110668980A (zh) * 2018-07-03 2020-01-10 浙江京新药业股份有限公司 一种2-取代的高牛磺酸衍生物
AU2019314323A1 (en) * 2018-08-01 2021-03-18 Alzheon, Inc. Sulfopropanoic acid derivatives for treating neurodegenerative disorders
SG11202100767XA (en) * 2018-08-01 2021-02-25 Alzheon Inc Methods for treating neurodegenerative disorders
CN111170901A (zh) * 2018-11-13 2020-05-19 润佳(苏州)医药科技有限公司 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途
CA3144008A1 (en) 2019-06-17 2020-12-24 Alzheon, Inc. Methods for treating neurodegenerative disorders
CN116059192A (zh) 2019-11-13 2023-05-05 润佳(苏州)医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
WO2023212289A1 (en) 2022-04-28 2023-11-02 Alzheon, Inc. Tramiprosate for treating apoe4-related diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
ATE262592T1 (de) * 1992-10-13 2004-04-15 Univ Duke Verfahren zum nachweis der alzheimer krankheit
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US20060079578A1 (en) * 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
JP2007502418A (ja) 2003-08-11 2007-02-08 カリフォルニア・インスティテュート・オブ・テクノロジー 微量流体大規模集積
PL3851447T3 (pl) 2006-10-12 2024-03-04 Bellus Health Inc. Sposoby, związki, kompozycje i nośniki dostarczające kwas 3-amino-1-propanosulfonowy
CN102838532A (zh) 2006-11-24 2012-12-26 Ac免疫有限公司 用于治疗与淀粉样物质或淀粉样蛋白有关的疾病的吡唑胺和噻唑胺衍生物
WO2012006329A2 (en) * 2010-07-06 2012-01-12 Genomind, Llc Apoe4 and apoj biomarker-based prevention and treatment of dementia
US10449177B2 (en) 2010-08-19 2019-10-22 Buck Institute For Research On Aging Methods of treating mild cognitive impairment (MCI) and related disorders
HUE044737T2 (hu) 2013-05-06 2019-11-28 Baxalta Inc Alzheimer-kór szubpopulációk kezelése egyesített immunglubulin G-vel
KR20230056800A (ko) * 2014-02-08 2023-04-27 제넨테크, 인크. 알츠하이머 질환을 치료하는 방법
WO2017044840A1 (en) 2015-09-10 2017-03-16 Alzheon, Inc. Methods of treating neurodegenerative disorders in a particular patient population
US20180250249A1 (en) 2016-02-02 2018-09-06 Alzheon, Inc. Methods of treating neurodegenerative disorders in a particular population

Also Published As

Publication number Publication date
US20230087041A1 (en) 2023-03-23
RS64744B1 (sr) 2023-11-30
JP2020109123A (ja) 2020-07-16
KR102645633B1 (ko) 2024-03-11
EP3119911A2 (en) 2017-01-25
ES2960625T3 (es) 2024-03-05
SI3119911T1 (sl) 2023-12-29
AU2015230972B2 (en) 2021-05-27
AU2015230972A1 (en) 2016-09-15
CA2941415A1 (en) 2015-09-24
WO2015143447A2 (en) 2015-09-24
JP2022159555A (ja) 2022-10-17
EP4289820A2 (en) 2023-12-13
EP4289820A3 (en) 2024-03-13
JP6588962B2 (ja) 2019-10-09
HUE063369T2 (hu) 2024-01-28
JP2019065044A (ja) 2019-04-25
US10471029B2 (en) 2019-11-12
JP2017511377A (ja) 2017-04-20
EP3119911B1 (en) 2023-08-09
PL3119911T3 (pl) 2024-01-22
US20170172952A1 (en) 2017-06-22
US20200101031A1 (en) 2020-04-02
PT3119911T (pt) 2023-11-03
EP3119911A4 (en) 2017-12-13
KR102448386B1 (ko) 2022-09-28
CN106170563A (zh) 2016-11-30
WO2015143447A3 (en) 2016-01-14
LT3119911T (lt) 2023-10-10
KR20160128391A (ko) 2016-11-07
HRP20231172T1 (hr) 2024-01-05
FI3119911T3 (fi) 2023-09-27
KR20220136476A (ko) 2022-10-07

Similar Documents

Publication Publication Date Title
DK3119911T3 (da) Forbindelser til anvendelse til behandling af alzheimers sygdom hos apoe4+/+ patienter
DK3347030T3 (da) Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme
MA45192A (fr) Traitement d'association
DK3134386T3 (da) Isoindolin-1-on-derivater med kolinerg muscarin-m1-receptor-positiv allosterisk modulatoraktivitet til behandling af alzheimers sygdom
IL285722A (en) Methods for treating Alzheimer's disease
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3119397T3 (da) Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
GB201500314D0 (en) Pharmaceutical formulations for the treatment of pulmonary arterial hypertension
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3474802T3 (da) Medicinsk forbinding
DK3265087T3 (da) Fremgangsmåde til behandling med tradipitant
DK3151851T3 (da) Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af komplement-medierede sygdomme hos patienter med c5-polymorfisme
DK3347002T3 (da) Behandling af alzheimers sygdom i en bestemt patientpopulation
DK3463351T3 (da) Behandling til parkinsons sygdom
DK3149049T3 (da) Il-22 til anvendelse til behandling af stofskiftesygdomme
DK3125874T3 (da) Et terapeutisk middel til anvendelse i behandlingen af infektioner
HK1243709A1 (zh) 可用於治療阿爾茨海默氏病的四氫呋喃稠合的氨基氫噻嗪衍生物
DK3096775T3 (da) SOCS-mimetika til behandling af sygdomme
DK3049099T3 (da) Amyloid-beta-bindende peptider og anvendelse deraf til terapi og diagnosticering af alzheimers demens
DE112015002229A5 (de) Formulierungen zur Behandlung von Hyperthyreose
DK3413870T3 (da) Igmesin til anvendelse ved behandlingen af alzheimers sygdom
DK3518801T3 (da) System til kirurgisk behandling
DK3137094T3 (da) Behandling og forebyggelse af alzheimers sygdom (ad)
KR20180085033A (ko) 피부 질환 치료용 약학적 제형 및 이의 제조 방법
DK3066475T3 (da) Biomarkører for progression af alzheimers sygdom